Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer

• Publication date

  2005-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.21478PMID 16247790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute doxorubicin cardiotoxicity.

  2005cited by this paper
• QT dispersion correlates with systolic rather than diastolic parameters in patients receiving anthracycline treatment.

  2004cited by this paper
• Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy.

  2002cited by this paper
• Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin

  2002cited by this paper
• Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat.

  2001cited by this paper
• Anthracycline-induced cardiotoxicity.

  2000influential reference
• Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry.

  2000cited by this paper
• QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide.

  2000cited by this paper
• Dose-response efficacy of valsartan, a new angiotensin II receptor blocker

  1999cited by this paper
• QT dispersion and late potentials during doxorubicin therapy for non‐Hodgkin’s lymphoma

  1999cited by this paper
• Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.

  1998cited by this paper
• Elevated B-type natriuretic peptide levels after anthracycline administration.

  1998cited by this paper
• Captopril ameliorates myocardial and hematological toxicities induced by adriamycin

  1998cited by this paper
• Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients

  1998cited by this paper
• AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS.

  1997cited by this paper
• Prolonged corrected QT dispersion.

  1997cited by this paper
• The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography.

  1997cited by this paper
• Clinically silent electrocardiographic abnormalities and risk of primary cardiac arrest among hypertensive patients.

  1996cited by this paper
• Anthracycline-Induced Cardiotoxicity

  1996cited by this paper
• ISIS-4 - A randomised factorial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58.050 patient with suspected acute myocardial-infarction.

  1995cited by this paper
• Stability of human atrial natriuretic peptide in blood samples.

  1994cited by this paper
• Variability of QT dispersion measurements in the surface electrocardiogram in patients with acute myocardial infarction and in normal subjects.

  1994cited by this paper
• Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure

  1994cited by this paper
• Stabilization of human brain natriuretic peptide in blood samples.

  1994cited by this paper
• Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

  1993cited by this paper
• Cardiac toxicity 4 to 20 years after completing anthracycline therapy.

  1991cited by this paper
• Doxorubicin-induced cardiac toxicity.

  1991cited by this paper
• Antiarrhythmic effect of amiodarone on doxorubicin acute toxicity in working rat hearts.

  1990cited by this paper
• Transesophageal echocardiography.

  1989cited by this paper
• Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

  1989cited by this paper
• Reproducibility of quantitative two-dimensional echocardiography.

  1988cited by this paper
• Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.

  1987cited by this paper
• Acute arrhythmogenicity of doxorubicin administration

  1987cited by this paper
• Acute Doxorubicin Cardiotoxicity: Functional, Metabolic, and Morphologic Alterations in the Isolated, Perfused Rat Heart

  1986cited by this paper
• Doxorubicin‐induced congestive heart failure in adults

  1985cited by this paper
• Overview of cardiac pathology in relation to anthracycline cardiotoxicity.

  1978cited by this paper
• QT Interval Prolongation as Predictor of Sudden Death in Patients with Myocardial Infarction

  1978cited by this paper
• QT interval prolongation as predictor of sudden death in patients with myocardial infarction.

  1978cited by this paper
• Minimization: A new method of assigning patients to treatment and control groups

  1974cited by this paper

• Role of Perindopril in Mitigating Doxorubicin’s Vascular Toxicity in a Rat Model

  2026cites this paper
• The emerging role of echocardiography-based techniques in cardio-onco-hematology

  2026cites this paper
• Insulin resistance: The central node of convergence between unfolded protein response, diabetes, and cancer.

  2026cites this paper
• Cancer therapy-induced cardiotoxicity: mechanisms and mitigations

  2025cites this paper
• Pharmacological prevention in cardio-oncology: from bench-to-bedside

  2025cites this paper
• Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study

  2025cites this paper
• Targeting autophagy in doxorubicin-induced cardiotoxicity: a comprehensive review of scientific landscapes and therapeutic innovations.

  2025cites this paper
• Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment

  2025cites this paper
• Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients

  2025cites this paper
• Prevention of anthracycline and trastuzumab‐induced decline in left ventricular ejection fraction with angiotensin‐converting enzyme inhibitors or angiotensin receptor blocker: a narrative systematic review of randomised controlled trials

  2024cites this paper
• Natural Products for Preventing and Managing Anthracycline-Induced Cardiotoxicity: A Comprehensive Review

  2024cites this paper
• Research progress on the role and mechanism of Sirtuin family in doxorubicin cardiotoxicity.

  2024cites this paper
• Statins for attenuating cardiotoxicity in patients receiving anthracyclines: a systematic review and meta-analysis.

  2023cites this paper
• Diabetes management in cancer patients. An Italian Association of Medical Oncology, Italian Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paper

  2023cites this paper
• Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies.

  2023cites this paper
• Cardiotoxicity in autologous haematopoietic stem cell transplantation for systemic sclerosis

  2023cites this paper
• Nanotechnology Approaches for Prevention and Treatment of Chemotherapy-Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors.

  2023cites this paper
• Losartan Reduces Remodeling and Apoptosis in an Adriamycin-Induced Cardiomyopathy Rat Model

  2023cites this paper
• Novel Therapeutics for Anthracycline Induced Cardiotoxicity

  2022cites this paper
• Prevention of Anthracycline-Induced Cardiotoxicity: The Good and Bad of Current and Alternative Therapies

  2022cites this paper
• Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysis.

  2022cites this paper
• Differential Impact of Doxorubicin Dose on Cell Death and Autophagy Pathways during Acute Cardiotoxicity

  2022cites this paper
• Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies

  2022cites this paper
• Cardioprotective Strategies from Cardiotoxicity in Cancer Patients: A Comprehensive Review

  2022cites this paper
• PREVENTION AND MANAGEMENT OF ANTHRACYCLINE INDUCED CARDIOTOXICITY: A REVIEW

  2022cites this paper
• Inequity in Cardio‐Oncology: Identifying Disparities in Cardiotoxicity and Links to Cardiac and Cancer Outcomes

  2021cites this paper
• How I treat cardiovascular complications in patients with lymphoid malignancies.

  2021cites this paper
• Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial

  2021cites this paper
• Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications

  2021cites this paper
• Ways of medicinal prevention and treatment of doxorubicin-induced cardiomyopathy in oncological patients

  2021cites this paper
• Protective Effects of ACEI/ARB on Left Ventricular Function in Anthracycline-Induced Chronic Cardiotoxicity: A Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin

  2021cites this paper
• Monitoring of Metabolic Syndrome and Cardiovascular Disease in Childhood Cancer Survivors

  2021cites this paper
• Cardiac remodeling after anthracycline and radiotherapy exposure in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study

  2021cites this paper
• Ways of medicinal prevention and treatment of doxorubicin-induced cardiomyopathy in oncological patients

  2021cites this paper
• Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer

  2021cites this paper
• Vanillin Prevents Doxorubicin-Induced Apoptosis and Oxidative Stress in Rat H9c2 Cardiomyocytes

  2020cites this paper
• Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system—from molecular mechanisms to therapeutic applications

  2020cites this paper
• The Role of Antioxidants in Ameliorating Cyclophosphamide-Induced Cardiotoxicity

  2020cites this paper
• Cardiotoxicity of Anthracyclines

  2020cites this paper
• Antioxidant Approach as a Cardioprotective Strategy in Chemotherapy-Induced Cardiotoxicity

  2020cites this paper
• Cardio-Oncology and Heart Failure

  2020cites this paper
• Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

  2020cites this paper
• Complications cardiaques des traitements anticancéreux

  2020cites this paper
• Cardio-Oncology Preventive Care: Racial and Ethnic Disparities

  2020cites this paper
• Protective effects of valsartan administration on doxorubicin-induced myocardial injury in rats and the role of oxidative stress and NOX2/NOX4 signaling

  2020cites this paper
• Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis

  2020cites this paper
• Complete atrioventricular block and torsade de pointes due to dose-dense epirubicin and cyclophosphamide therapy

  2020cites this paper
• Srčno popuščanje in onkološko zdravljenje

  2020cites this paper
• Cardiac imaging in cardiotoxicity: a focus on clinical practice

  2020cites this paper
• Oncologic therapies associated with cardiac toxicities: how to minimize the risks

  2019cites this paper
• Cardiotoxicidad por trastuzumab en pacientes con cáncer de mama. Serie de casos

  2019influential citation
• Cardiooncology. Basic principles of prevention and treatment of cardiotoxicity in cancer patients

  2019cites this paper
• Arterial hypertension in cancer: The elephant in the room.

  2019cites this paper
• Onco-Cardiology for Breast Cancer

  2019cites this paper
• Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors

  2019cites this paper
• Antineoplastic Therapies related Cardiotoxicity

  2019cites this paper
• TCRM_A_215857 1095..1110

  2019cites this paper
• Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence

  2019cites this paper
• Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention

  2018cites this paper
• Victims of Our Own Success: Cardiac Toxicities from Conventional and Emerging Cancer Therapies

  2018cites this paper
• Arterial Hypertension

  2018cites this paper
• Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I

  2018cites this paper
• Prevention and Clinical Management of Cardiovascular Damage Induced by Anticancer Drugs: Need for Early Biomarkers and Cardio- and Vasculoprotection in Personalized Therapy

  2018cites this paper
• Mitochondrial ROS‐induced ERK1/2 activation and HSF2‐mediated AT1R upregulation are required for doxorubicin‐induced cardiotoxicity

  2018cites this paper
• Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.

  2018cites this paper
• Renin–Angiotensin System Inhibitors to Mitigate Cancer Treatment–Related Adverse Events

  2018cites this paper
• Update on pathophysiology and preventive strategies of anthracycline‐induced cardiotoxicity

  2018cites this paper
• Protecting the heart in cancer therapy

  2018cites this paper
• Mechanism and Prevention of Cardiomyopathy Due to Chemotherapy

  2018cites this paper
• Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.

  2018cites this paper
• 27 Anthracycline Cardiotoxicity

  2018cites this paper
• Left Ventricular Dysfunction and Chemotherapeutic Agents

  2018cites this paper
• Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective

  2018cites this paper
• Valsartan regulates TGF-β/Smads and TGF-β/p38 pathways through lncRNA CHRF to improve doxorubicin-induced heart failure

  2018cites this paper
• In vitro evaluation of anthracycline-induced cardiotoxicity and mitigation by perturbation of angiotensin signalling

  2018cites this paper
• Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy : biomarkers : detection and treatment of cardiotoxicity

  2017cites this paper
• Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?

  2017cites this paper
• Cardiac-Oncology: Management of the Patient with Heart Failure After Chemotherapy

  2017cites this paper
• Angiotensin-Converting Enzyme Inhibition

  2017cites this paper
• Management of Heart Failure in Cancer Patients and Cancer Survivors.

  2017cites this paper
• Cardio-oncology Related to Heart Failure: Pediatric Considerations for Cardiac Dysfunction.

  2017cites this paper
• Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts

  2017cites this paper
• Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications.

  2017cites this paper
• From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview

  2017cites this paper
• Cardiotoxicity Induced by Anticancer Drugs—the Role of Biomarkers

  2017cites this paper
• Cardiotoxicity of Anticancer Therapies

  2017cites this paper
• Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives

  2017cites this paper
• Cardiovascular complications of multiple myeloma in the elderly

  2017cites this paper
• Chemotherapy Agents With Known Cardiovascular Side Effects and Their Anesthetic Implications.

  2017cites this paper
• Valsartan regulates TGF-β/Smads and TGF-β/p38 pathways through lncRNA CHRF to improve doxorubicin-induced heart failure

  2017cites this paper
• Cardio‐Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction

  2017cites this paper
• Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients

  2017cites this paper
• Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice

  2017cites this paper
• High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury

  2017cites this paper
• Protecting the Heart in Cancer Patients: The Role of Cardio-Oncology

  2017cites this paper
• Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy

  2017cites this paper
• Estrategias de prevención de cardiotoxicidad Preventive strategies of cardiotoxicity

  2016cites this paper
• Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients

  2016cites this paper
• Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss

  2016cites this paper